重组白细胞介素2对乙肝e抗原阳性慢性肝炎的作用
Effect of recombinant interleukin 2 on hepatitis B e antigen positive chronic hepatitis.
作者信息
Onji M, Kondoh H, Horiike N, Yamaguchi S, Ogawa Y, Kumon I, Ohta Y
机构信息
Third Department of Internal Medicine, Ehime University School of Medicine, Japan.
出版信息
Gut. 1987 Dec;28(12):1648-52. doi: 10.1136/gut.28.12.1648.
Eleven patients with hepatitis B (HB) virus related chronic hepatitis were treated with recombinant interleukin 2 (rIL 2). Two hundred and fifty to 1000 units were given intravenously once daily for seven to 28 days. In five patients serum glutamic pyruvic transaminase activity rose transiently. Six patients showed a decrease in HBV DNA polymerase. One patient lost HBs, e antigens (Ags) and gained anti-HBs, e antibodies, while one lost HBs Ag and another HBe Ag. 2'-5' oligoadenylate synthetase activity in mononuclear cells in the peripheral blood did not change during treatment. The number of CD4 positive (helper/inducer) cells and natural killer cell activity increased after therapy (p less than 0.05, p less than 0.01). These results suggest that rIL 2 acts as an immunomodulatory agent enhancing host immune activity and may be beneficial in patients with chronic HB virus infection.
11例乙型肝炎（HB）病毒相关性慢性肝炎患者接受了重组白细胞介素2（rIL 2）治疗。每天静脉注射250至1000单位，持续7至28天。5例患者血清谷丙转氨酶活性短暂升高。6例患者的HBV DNA聚合酶降低。1例患者失去了HBs、e抗原（Ags），并产生了抗-HBs、e抗体，1例患者失去了HBs Ag，另1例失去了HBe Ag。治疗期间外周血单核细胞中的2'-5'寡腺苷酸合成酶活性未发生变化。治疗后CD4阳性（辅助/诱导）细胞数量和自然杀伤细胞活性增加（p<0.05，p<0.01）。这些结果表明，rIL 2作为一种免疫调节剂可增强宿主免疫活性，可能对慢性HB病毒感染患者有益。
Zotero 插件